EyRIS, a Singapore-based healthcare technology company specialising in artificial intelligence (AI) healthcare solutions, and Optometrist Warehouse, part of the Chemist Warehouse Group in Australia, have signed a Memorandum of Understanding (MOU) to collaborate on a ground-breaking study focused on the effectiveness of AI in screening diabetic retinopathy.
The collaboration marks a significant milestone in the field of healthcare, showcasing the potential benefits of AI-driven solutions in improving patient outcomes and cost-effectiveness.
Diabetic retinopathy, a common complication of diabetes, is a leading cause of blindness among adults globally. According to the Australian Diabetes Society, over 1.5 million Australians are currently living with diabetes, and this number is projected to increase significantly over the next decade.
Early detection and intervention are crucial to prevent vision loss and related complications.
The joint study will leverage EyRIS’s advanced AI algorithms and Optometrist Warehouse expertise with links to the extensive network of Chemist Warehouse pharmacies across Australia to evaluate the effectiveness of AI-driven screening for diabetic retinopathy.
By using EyRIS’s cutting-edge technology, which analyses retinal images for signs of diabetic retinopathy, the study aims to demonstrate the efficacy and efficiency of AI in identifying patients at risk and facilitating early intervention.
EyRIS CEO Mr Lai Teik Kin said the company is thrilled to partner with Optometrist Warehouse on the ground-breaking study.
“By harnessing the power of AI, we can revolutionise diabetic retinopathy screening, ensuring early detection and timely treatment for patients. Our technology has the potential to transform healthcare delivery, saving lives and reducing healthcare costs.”
Mr Peter Larsen, managing director of Optometrist Warehouse, whose mission is to transform health outcomes by systematically connecting pharmacy with optometry, said it recognises the transformative impact of AI in the field of medicine.
“We are proud to collaborate with EyRIS to explore the possibilities of AI in diabetic retinopathy screening. This study aligns with our mission to improve healthcare outcomes for all Australians. By leveraging EyRIS’s AI expertise, we can enhance the accessibility and affordability of early screening, thereby empowering patients and healthcare providers alike,” Larsen said.
The companies said the collaboration underscores the commitment of both organisations to leverage technological advancements for the betterment of healthcare.
The potential benefits of AI-driven diabetic retinopathy screening include reducing the burden on healthcare systems, minimising unnecessary referrals, and enabling targeted interventions, ultimately improving patient outcomes, they said.
The study will span a period of 36 months and involve a large sample size of diabetic patients across various regions in Australia.
More reading
Chemist Warehouse and Peter Larsen join forces to ‘disrupt’ optometry industry
US investor backs Australian AI innovation, Eyetelligence
Artificial intelligence: eyecare’s friend of foe?
